Trial Profile
Phase II trial of IRX 4204 in patients with advanced prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs IRX 4204 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Io Therapeutics
- 23 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 05 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 05 May 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.